0001419554 false 0001419554 2023-09-12 2023-09-12 0001419554 BBLG:CommonStockParValue0.001PerShareMember 2023-09-12 2023-09-12 0001419554 BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember 2023-09-12 2023-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 12, 2023

 

 

 

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40899   42-1743430

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2 Burlington Woods Drive, Ste. 100

Burlington, MA

  01803
(Address of principal executive offices)   (Zip Code)

 

(Registrant’s telephone number, including area code): (781) 552-4452

 

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BBLG   Nasdaq Capital Market
         
Warrants to Purchase Common Stock, $0.001 par value per share   BBLGW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting of Stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), held on September 12, 2023, the Company’s stockholders voted on the matters described below.

 

Proposal 1. The Company’s stockholders elected the following four director nominees to serve until the date of the next Annual Meeting of stockholders following the date such persons are elected as directors, and until their successors are duly elected and qualified. The results of the vote are summarized in the table below.

 

Director Nominees   Votes For   Votes Withheld   Broker Non-Votes
Don Hankey   1,213,254   82,980   578,270
Bruce Stroever   1,213,204   83,030   578,270
Erick Lucera   1,213,143   83,091   578,270
Siddhesh Angle   1,212,354   83,880   578,270

 

Proposal 2. The Company’s stockholders approved, on an advisory basis, the Company’s executive compensation. The results of the vote are summarized in the table below.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
904,764   84,094   307,376   578,270

 

Proposal 3. The Company’s stockholders approved, on an advisory basis, that future say-on-pay votes should occur every year. The results of the vote are summarized in the table below.

 

1 Year   2 Years   3 Years   Abstentions   Broker Non-Votes
958,400   22,823   2,726   312,285   578,270

 

Based on these results and consistent with the majority of votes cast with respect to this matter, the Board of Directors of the Company has adopted a policy to hold an advisory vote on compensation of the Company’s named executive officers every year.

 

Proposal 4. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote are summarized in the table below.

 

Votes For   Votes Against   Abstentions
1,513,051   61,316   300,137

 

Proposal 5. The Company’s stockholders approved the First Amendment to the Company’s 2015 Equity Incentive Plan. The results of the vote are summarized in the table below.

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
863,931   123,150   309,153   578,270

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BONE BIOLOGICS CORPORATION
   
Date: September 12, 2023    
  By: /s/ JEFFREY FRELICK
    Jeffrey Frelick, Chief Executive Officer

 

 

v3.23.2
Cover
Sep. 12, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 12, 2023
Entity File Number 001-40899
Entity Registrant Name BONE BIOLOGICS CORPORATION
Entity Central Index Key 0001419554
Entity Tax Identification Number 42-1743430
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Burlington Woods Drive
Entity Address, Address Line Two Ste. 100
Entity Address, City or Town Burlington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01803
City Area Code (781)
Local Phone Number 552-4452
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.001 per share  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol BBLG
Security Exchange Name NASDAQ
Warrants to Purchase Common Stock, $0.001 par value per share  
Title of 12(b) Security Warrants to Purchase Common Stock, $0.001 par value per share
Trading Symbol BBLGW
Security Exchange Name NASDAQ

Bone Biologics (NASDAQ:BBLG)
過去 株価チャート
から 4 2024 まで 5 2024 Bone Biologicsのチャートをもっと見るにはこちらをクリック
Bone Biologics (NASDAQ:BBLG)
過去 株価チャート
から 5 2023 まで 5 2024 Bone Biologicsのチャートをもっと見るにはこちらをクリック